GLOBUS MEDICAL INC

Except as set forth below, during the quarter ended December 31, 2025, none of our directors or officers (as defined in Rule 16a-1 under the Exchange Act)adopted, modified orterminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement” (as those terms are defined in Item 408 of Regulation S-K).

On November 12, 2025, Kelly G. Huller, the Company's Executive Vice President and General Counsel, adopted a trading plan intended to satisfy the condition under Rule 10b5-1(c) of the Exchange Act. Ms. Huller’s Rule 10b5-1 trading plan has a term ending upon the earlier of (i)February 7, 2027 or (ii) the sale of all shares subject to the plan and provides for the sale of up to 67,500 shares of Class A Common pursuant to the terms of the plan.

On December 10, 2025, David D. Davidar, amember of the Board, adopted a trading plan intended to satisfy the conditions under Rule 10b5-1(c) of the Exchange Act. Mr. Davidar’s Rule 10b5-1 trading plan has a term ending upon the earlier of (i)December 31, 2026 or (ii) the sale of all shares subject to the plan and provides for the sale of up to 36,000 shares of Class A Common pursuant to the terms of the plan.

On December 10, 2025, Berachah Foundation (David D. Davidar's Foundation), a foundation of amember of the Board, adopted a trading plan intended to satisfy the conditions under Rule 10b5-1(c) of the Exchange Act. The foundation’s Rule 10b5-1 trading plan has a term ending upon the earlier of (i)December 31, 2026 or (ii) the sale of all shares subject to the plan and provides for the sale of up to 9,100 shares of Class A Common pursuant to the terms of the plan.